Top Performing Pharmaceutical ETFs: Your Guide to the Best Healthcare Funds in 2026

Investors seeking diversified exposure to the pharmaceutical sector increasingly turn to ETFs as a strategic investment vehicle. Whether you’re an experienced trader or just beginning your investment journey, selecting the best pharma ETF can significantly impact your portfolio performance. Rather than purchasing individual pharmaceutical stocks, these funds offer a convenient way to access multiple top pharma companies through a single security that trades like a stock.

The primary appeal of pharmaceutical exchange-traded funds lies in their ability to provide broad sector exposure while maintaining the liquidity and simplicity of stock trading. By holding multiple pharma holdings, these funds typically exhibit lower price swings compared to individual pharmaceutical stocks. Even when certain holdings experience dramatic moves, the overall fund value tends to be stabilized by other positions within the portfolio. This risk reduction is particularly valuable for investors seeking consistent growth in the healthcare sector.

Why Pharmaceutical ETFs Rank Among the Best Investment Choices for Healthcare Exposure

The best pharma ETF selection depends on your specific investment goals and risk tolerance. Investors can choose from funds focused exclusively on U.S. pharmaceutical companies, those emphasizing specific therapeutic areas like oncology or vaccines, or those providing international healthcare exposure. Many leading funds feature diverse holdings spanning pain management, biotechnology innovations, immunology, and vaccine development—allowing you to participate in multiple pharma industry segments without managing individual stock positions.

Data analyzed from ETFdb.com as of early 2026 highlights five outstanding pharmaceutical exchange-traded funds worth considering. Each fund presents distinct characteristics in terms of assets under management, cost structure, and portfolio composition.

The Five Best Pharmaceutical ETFs Ranked by Total Assets Under Management

VanEck Pharmaceutical ETF (NASDAQ: PPH) — Premium Choice for Focused Pharma Exposure

Total assets under management: US$1.2 billion
Expense ratio: 0.36 percent

Launched in late 2011, this best-in-class pharma ETF tracks the MVIS US Listed Pharmaceutical 25 Index, offering concentrated exposure to the sector’s leading companies. With 26 holdings focused on top pharmaceutical names, it delivers meaningful upside potential despite inherent sector risks. Investment analysts recommend this fund for those seeking targeted pharmaceutical sector participation.

The fund’s top five holdings include Eli Lilly, Novartis, Merck & Company, Novo Nordisk, and Bristol-Myers Squibb—representing the pharmaceutical industry’s most influential players.

iShares US Pharmaceuticals ETF (ARCA: IHE) — Comprehensive U.S. Pharma Portfolio

Total assets under management: US$959.17 million
Expense ratio: 0.38 percent

Established in May 2006, the iShares platform delivers one of the best pharma ETF options for capturing broad U.S. pharmaceutical sector dynamics. This fund maintains 45 holdings predominantly composed of large-cap pharmaceutical corporations, providing stability through diversification.

Johnson & Johnson and Eli Lilly represent the fund’s largest positions, collectively accounting for approximately 45 percent of assets. Additional significant holdings include Merck & Company, Bristol-Myers Squibb, and Zoetis, creating a well-balanced pharmaceutical investment vehicle.

Invesco Pharmaceuticals ETF (ARCA: PJP) — Value-Focused Healthcare Strategy

Total assets under management: US$385.21 million
Expense ratio: 0.57 percent

Created in June 2005, the Invesco offering specializes in U.S.-based pharmaceutical companies selected through rigorous investment criteria including valuation metrics and risk assessments. Managing 31 securities, this fund appeals to value-oriented investors examining the pharmaceutical sector.

Leading positions consist of Merck & Company, Johnson & Johnson, Eli Lilly, Pfizer, and Abbott Laboratories—combining established pharmaceutical innovators with proven market track records.

State Street SPDR S&P Pharmaceuticals ETF (ARCA: XPH) — Broad-Based Sector Representation

Total assets under management: US$234.14 million
Expense ratio: 0.35 percent

Introduced in June 2006, this pharma ETF represents the pharmaceutical sub-sector component of the S&P Total Market Index. With 52 holdings and relatively balanced weighting across positions, XPH distinguishes itself through more evenly distributed exposure compared to competitors.

The fund’s top holdings include MBX Biosciences, Mind Medicine, Organon & Company, Axsome Therapeutics, and Liquidia, reflecting its commitment to capturing diverse pharmaceutical market segments.

KraneShares MSCI All China Health Care Index ETF (ARCA: KURE) — International Pharma Expansion

Total assets under management: US$86.81 million
Expense ratio: 0.65 percent

This best-in-class international pharma option launched in February 2018, providing exposure to large and mid-cap Chinese healthcare enterprises weighted by market value. The fund tracks 50 healthcare holdings capturing the rapidly growing Asian pharmaceutical market.

Principal holdings include BeOne Medicines, Jiangsu Hengrui Medicine, WuXi Biologics, Innovent Biologics, and Akeso, representing the pharmaceutical sector’s most prominent Chinese market participants.

Evaluating the Best Pharma ETF for Your Portfolio

Cost efficiency matters significantly when selecting the best pharmaceutical exchange-traded fund. Expense ratios ranging from 0.35 to 0.65 percent directly impact long-term returns, making fund selection an important consideration. The State Street SPDR S&P Pharmaceuticals ETF offers the lowest expense ratio at 0.35 percent, while most major pharma funds maintain competitive fee structures below 0.60 percent.

Your investment objectives should guide your pharmaceutical ETF choice. Domestic-focused investors might consider the iShares or VanEck offerings, while those seeking international diversification should explore the KraneShares China-focused option. Each represents a valid approach to pharma sector participation through professionally managed, diversified investments.

This analysis reflects data gathered during early 2026. The pharmaceutical sector continues evolving as new therapies, regulatory changes, and market dynamics reshape the industry landscape.

Disclosure: This article provides informational content only and does not constitute investment advice. Investors should conduct thorough research and consult financial advisors before making investment decisions.